Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3335 | Repeat SARS-CoV-2 IgG antibodies at 45-65 days Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The objectives of this proposal are to: 1) determine the rate of SARS-CoV-2 seroconversion in unselected pregnant women in Hong Kong; 2) determine the rate of SARS-CoV-2 infection in women presenting with miscarriage and stillbirth; 3) follow the pregnancy course and perinatal outcome of confirmed COVID-19-infected pregnant cases; 4) determine the risk and characteristics of vertical transmission; and 5) evaluate the placental barrier, immune response and fetal damage in vertical transmission of SARS-CoV-2. A series of longitudinal and cross-sectional observational studies, and a laboratory-based study will be conducted to fulfil the 5 objectives.
Description: Mother
Measure: Seroconversion during pregnancy - DSS1 Time: At DSS1 (Around 11-13 weeks gestation)Description: Mother
Measure: Seroconversion during pregnancy - At delivery Time: At DeliveryDescription: Mother (1st); Mother and abortus/stillborn baby(2nd)
Measure: Pregnancy loss Time: At pregnancy lossDescription: Mother and Baby
Measure: Pregnancy course and perinatal outcome Time: From date of recruited until the date of deliveryDescription: Mother and Baby
Measure: Vertical transmission Time: At Newborn 0 hours of life, mother immediately after deliveryDescription: Mother and Baby
Measure: Vertical transmission Time: At Newborn 7 days of lifeDescription: Mother and Baby
Measure: Vertical transmission Time: At Newborn 14 days of lifeDescription: Mother and Baby
Measure: Vertical transmission Time: At Newborn 6 months of lifeDescription: Mother and Baby
Measure: Vertical transmission Time: At Newborn 18 months of lifeDescription: Mother and Baby
Measure: Potential mechanisms for vertical transmission 1) placental barrier, 2) immune response and 3) fetal damage of vertical transmission and mechanism in SARS-CoV-2 infection. Time: through study completion, up to 2 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports